NUREXONE BIOLOGIC INC. (J90) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has a cash flow conversion efficiency ratio of -0.426x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.17 Million ≈ $-1.37 Million USD) by net assets (€2.76 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of NUREXONE BIOLOGIC INC. for the company's overall valuation and market capitalisation.
NUREXONE BIOLOGIC INC. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how NUREXONE BIOLOGIC INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
NUREXONE BIOLOGIC INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their cash flow conversion efficiency. See J90 cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pioneer Power Solutions Inc.
NASDAQ:PPSI
|
-0.033x |
|
TJ media Co. Ltd
KQ:032540
|
0.033x |
|
Urbanise.com Ltd
AU:UBN
|
-0.242x |
|
Piolink Inc
KQ:170790
|
0.042x |
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
0.188x |
|
Bedmutha Industries Limited
NSE:BEDMUTHA
|
0.440x |
|
TPC Consolidated Ltd
AU:TPC
|
0.228x |
|
Harrisons Malayalam Limited
NSE:HARRMALAYA
|
0.033x |
Annual Cash Flow Conversion Efficiency for NUREXONE BIOLOGIC INC. (2021–2025)
The table below shows the annual cash flow conversion efficiency of NUREXONE BIOLOGIC INC. from 2021 to 2025. View today's stock price for NUREXONE BIOLOGIC INC. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.76 Million ≈ $3.22 Million |
€-4.51 Million ≈ $-5.27 Million |
-1.636x | +41.07% |
| 2024-12-31 | €1.76 Million ≈ $2.06 Million |
€-4.89 Million ≈ $-5.71 Million |
-2.776x | +82.16% |
| 2023-12-31 | €189.00K ≈ $220.96K |
€-2.94 Million ≈ $-3.44 Million |
-15.561x | -747.60% |
| 2022-12-31 | €2.10 Million ≈ $2.45 Million |
€-3.85 Million ≈ $-4.50 Million |
-1.836x | -75.39% |
| 2021-12-31 | €1.18 Million ≈ $1.38 Million |
€-1.23 Million ≈ $-1.44 Million |
-1.047x | -- |
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more